JP2003533465A - 迅速崩壊固体経口投与形態 - Google Patents

迅速崩壊固体経口投与形態

Info

Publication number
JP2003533465A
JP2003533465A JP2001583733A JP2001583733A JP2003533465A JP 2003533465 A JP2003533465 A JP 2003533465A JP 2001583733 A JP2001583733 A JP 2001583733A JP 2001583733 A JP2001583733 A JP 2001583733A JP 2003533465 A JP2003533465 A JP 2003533465A
Authority
JP
Japan
Prior art keywords
less
composition
dosage form
water
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001583733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533465A5 (enExample
Inventor
エー． ジャイン，ラジーブ
ビー． ラディー，スティーブン
イアイン カミング，ケネス
ジョセフ アンソニー クランシー，モーリス
エリザベス コッド，ジャネット
Original Assignee
エラン ファーマ インターナショナル，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン ファーマ インターナショナル，リミティド filed Critical エラン ファーマ インターナショナル，リミティド
Publication of JP2003533465A publication Critical patent/JP2003533465A/ja
Publication of JP2003533465A5 publication Critical patent/JP2003533465A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001583733A 2000-05-18 2001-05-18 迅速崩壊固体経口投与形態 Withdrawn JP2003533465A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/572,961 2000-05-18
US09/572,961 US6316029B1 (en) 2000-05-18 2000-05-18 Rapidly disintegrating solid oral dosage form
PCT/US2001/015983 WO2001087264A2 (en) 2000-05-18 2001-05-18 Rapidly disintegrating solid oral dosage form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010227452A Division JP2011037876A (ja) 2000-05-18 2010-10-07 迅速崩壊固体経口投与形態

Publications (2)

Publication Number Publication Date
JP2003533465A true JP2003533465A (ja) 2003-11-11
JP2003533465A5 JP2003533465A5 (enExample) 2008-12-18

Family

ID=24290082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001583733A Withdrawn JP2003533465A (ja) 2000-05-18 2001-05-18 迅速崩壊固体経口投与形態
JP2010227452A Pending JP2011037876A (ja) 2000-05-18 2010-10-07 迅速崩壊固体経口投与形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010227452A Pending JP2011037876A (ja) 2000-05-18 2010-10-07 迅速崩壊固体経口投与形態

Country Status (8)

Country Link
US (1) US6316029B1 (enExample)
EP (1) EP1282399B1 (enExample)
JP (2) JP2003533465A (enExample)
AT (1) ATE333265T1 (enExample)
AU (1) AU2001263228A1 (enExample)
CA (1) CA2408848C (enExample)
DE (1) DE60121570T2 (enExample)
WO (1) WO2001087264A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007197373A (ja) * 2006-01-27 2007-08-09 Akiyama Jozai Kk 口腔内速崩錠の製造方法
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
JP2008189634A (ja) * 2007-02-08 2008-08-21 Akiyama Jozai Kk 口腔内速崩錠の製造方法
JP2008535846A (ja) * 2005-04-08 2008-09-04 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物
JP2009544706A (ja) * 2006-07-24 2009-12-17 シマ ラブス インク． 高用量の経口的に溶解可能／分解可能な凍結乾燥剤形
JP2011524386A (ja) * 2008-06-20 2011-09-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 直接圧縮性および迅速崩壊性錠剤マトリックス
JP2016513625A (ja) * 2013-03-04 2016-05-16 ブイティーブイ・セラピューティクス・エルエルシー 安定なグルコキナーゼ活性化剤組成物
JPWO2015016256A1 (ja) * 2013-07-30 2017-03-02 ライオン株式会社 錠剤
JP2019077644A (ja) * 2017-10-25 2019-05-23 富士フイルム株式会社 医薬組成物及び医薬組成物の製造方法

Families Citing this family (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
CA2348452A1 (en) * 1998-10-27 2000-05-04 Biovail Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
DE19931708A1 (de) 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20100010101A1 (en) * 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US20040043061A1 (en) * 2000-09-15 2004-03-04 Leon Daniel S. Dissolvable films comprising suspended, non-soluble pharmaceutically active ingredients, apparatus and methods for their manufacture and use
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US6559180B2 (en) 2001-03-27 2003-05-06 Yuri Busiashvili Nitroglycerin-menthol potentiation for treatment of angina
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
WO2003000228A2 (en) * 2001-06-22 2003-01-03 Elan Pharma International Ltd. Method for high through put screening using a small scale mill or microfluidics
PT1275377E (pt) * 2001-07-11 2003-11-28 Fidia Farmaceutici Granulados contendo substancias lipossoluveis e sua preparacao
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
EP1429736A2 (en) * 2001-09-26 2004-06-23 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
CN1602187A (zh) * 2001-10-10 2005-03-30 法马西亚公司 通过喷雾干燥法制备的口内崩解的伐地考昔组合物
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
CA2363528A1 (en) * 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
CN1688291A (zh) * 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US6941948B2 (en) * 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20050191357A1 (en) * 2002-03-20 2005-09-01 Yoshiaki Kawashima Method of manufacturing chemical-containing composite particles
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
ATE539737T1 (de) 2002-04-12 2012-01-15 Alkermes Pharma Ireland Ltd Nanopartikuläre megestrol- formulierungen
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US6592852B1 (en) * 2002-04-25 2003-07-15 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Zinc citrate beads in oral compositions
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US20030215498A1 (en) * 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2004047810A1 (en) * 2002-11-25 2004-06-10 Purdue Research Foundation Mannose-based fast dissolving tablets
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
KR20050088243A (ko) 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7390505B2 (en) * 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) * 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP4739217B2 (ja) * 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
JP2006525303A (ja) 2003-05-08 2006-11-09 ネクター セラピューティクス ユーケー リミティド 微粒子物質
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20060226234A1 (en) * 2003-06-11 2006-10-12 Kettinger Frederick R Pharmaceutical dosage forms having overt and covert markings for identification and authentification
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
ES2318330T3 (es) * 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050053655A1 (en) * 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
US20050112196A1 (en) * 2003-10-07 2005-05-26 Jianbo Xie Rapidly disintegrating formulation
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US20050196441A1 (en) * 2003-11-05 2005-09-08 Dvorsky James E. Quick dissolving agrochemical and animal health products
WO2005044234A2 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
US20070148232A1 (en) * 2003-12-31 2007-06-28 Pfizer Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers
US7785619B2 (en) * 2004-04-08 2010-08-31 Micro Nutrient, Llc Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
US20050226906A1 (en) * 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
US7850987B2 (en) * 2004-04-08 2010-12-14 Micronutrient, Llc Nutrient composition(s) and system(s) for individualized, responsive dosing regimens
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
WO2006018954A1 (ja) * 2004-08-17 2006-02-23 Eisai R & D Management Co., Ltd. ジブロモフルオロベンゼン誘導体の製造方法
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
EP2353590A1 (en) 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070065374A1 (en) * 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
MX2007011772A (es) * 2005-03-23 2007-12-05 Elan Pharma Int Ltd Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
US7825087B2 (en) * 2005-04-12 2010-11-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007035348A2 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
CA2626846A1 (en) * 2005-11-03 2007-05-18 Redpoint Bio Corporation Hydrazone derivatives and uses thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20070243248A1 (en) * 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
EP1891938A1 (en) * 2006-07-24 2008-02-27 Cephalon France High dose orally dissolvable/disintegrable lyophilized dosage form
WO2008024364A2 (en) * 2006-08-22 2008-02-28 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20080070865A1 (en) * 2006-09-15 2008-03-20 Redpoint Bio Corporation Triphenylphosphine oxide derivatives and uses thereof
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
RU2465907C2 (ru) * 2006-12-20 2012-11-10 Тева Вимен'С Хелс, Инк. Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм
EP1935405A1 (en) * 2006-12-22 2008-06-25 LEK Pharmaceuticals D.D. Orally disintegrating tablets
CA2677230A1 (en) * 2007-02-02 2008-08-14 Redpoint Bio Corporation Use of a trpm5 inhibitor to regulate insulin and glp-1 release
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2180873B1 (en) 2007-07-25 2018-04-11 3M Innovative Properties Company Therapeutic dental composition for use in the inhibition of biofilm formation in the oral cavity.
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009124357A1 (en) * 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
US20090269403A1 (en) * 2008-04-24 2009-10-29 Shaked Ze Ev Oral contraceptive dosage forms and methods of making such dosage forms
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010077878A1 (en) * 2008-12-15 2010-07-08 Fleming And Company, Pharmaceuticals Rapidly dissolving vitamin formulation and methods of using the same
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
EP2253306A1 (en) 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
JP6072539B2 (ja) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
SG178376A1 (en) 2009-09-04 2012-03-29 Redpoint Bio Corp Sweetness enhancers including rebaudioside a or d
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
AU2010298437B2 (en) 2009-09-22 2014-06-19 Redpoint Bio Corporation Novel polymorphs of rebaudioside C and methods for making and using the same
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
KR20130138768A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 신속-용해성 투여 형태
US10238684B2 (en) 2010-11-18 2019-03-26 Foundational Biosystems, Llc Micro- and nano-quantity sleep enhancing nutrient composition and method of enhancing central nervous system protein clearance using same
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
MX355785B (es) 2011-08-08 2018-04-30 Int Flavors & Fragrances Inc Composicions y metodos para la biosintesis de vainillina o de beta-d-glucosido de vainillina.
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
JP5877778B2 (ja) * 2012-05-28 2016-03-08 株式会社ホットアルバム炭酸泉タブレット 錠剤の製造方法及び錠剤
HUE034490T2 (en) 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
KR20160108828A (ko) 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
EP2880992A3 (en) 2013-12-05 2015-06-17 International Flavors & Fragrances Inc. Rebaudioside C and its stereoisomers as natural product sweetness enhancers
CA2888219C (en) * 2014-02-07 2018-07-10 Scilabs Pharmaceuticals, Inc. All natural, non-toxic sublingual drug delivery systems
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CA2957966C (en) * 2014-08-14 2021-11-30 Brown University Compositions for stabilizing and delivering proteins
RS59490B1 (sr) 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
WO2016118515A1 (en) 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
US11173098B1 (en) 2016-02-05 2021-11-16 Gram Tactical Llc Magazines for tactical medicine dispensers
HRP20220237T1 (hr) 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
PT3706739T (pt) 2017-11-12 2024-12-04 Biohaven Therapeutics Ltd Utilização de profármacos de riluzol para tratar ataxias
WO2019133712A1 (en) 2017-12-27 2019-07-04 Schinazi Raymond F Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
EP3508199A1 (en) * 2018-01-05 2019-07-10 Dompé farmaceutici S.p.A. Immediate-release pharmaceutical compositions containing ketoprofen lysine salt
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
CN109125775B (zh) * 2018-09-25 2021-02-09 广东爱车小屋电子商务科技有限公司 持久留香的空气清新剂及其制备方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020395254B2 (en) 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
JP7756097B2 (ja) * 2020-02-19 2025-10-17 ナノ ファーマソリューションズ， インコーポレイテッド 治療剤ナノ粒子および調製方法
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
IT202000025885A1 (it) 2020-10-30 2022-04-30 Vacutest Kima S R L Composizione conservante per urine, dispositivo per il campionamento di urine e metodo per la produzione di un dispositivo per il campionamento di urine
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
WO2022109076A1 (en) * 2020-11-19 2022-05-27 Nano Pharmasolutions, Inc. Dry powder antiviral compositions and their use for treating viral infection
WO2022155564A1 (en) 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
CA3221395A1 (en) 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
DE102024107710A1 (de) * 2024-03-18 2025-09-18 Glatt Gesellschaft Mit Beschränkter Haftung Verfahren zur Herstellung von Tabletten
DE102024107712A1 (de) * 2024-03-18 2025-09-18 Glatt Gesellschaft Mit Beschränkter Haftung Vorrichtung zur Herstellung von Tabletten
WO2026108769A1 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof
WO2026108771A2 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH07112936A (ja) * 1992-04-27 1995-05-02 Philippe Perovich 治療用成分、とくにアスピリンに基づく成分の製剤方法
WO2000013672A1 (en) * 1998-09-04 2000-03-16 Elan Pharma International Ltd New solid dose form of nanoparticulate naproxen

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403078A1 (fr) 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
WO1993025190A1 (en) * 1992-06-10 1993-12-23 Eastman Kodak Company Surface modified nsaid nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
PT914818E (pt) * 1996-06-14 2005-08-31 Kyowa Hakko Kogyo Kk Comprimido de desintegracao rapida por via intraoral
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
JP3182404B2 (ja) * 1998-01-14 2001-07-03 大日本製薬株式会社 口腔内崩壊錠及びその製造方法
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
JP3435664B2 (ja) * 1999-12-08 2003-08-11 ヤンセンファーマ株式会社 口腔内速崩壊型錠剤及びその製造方法
EP1239844B1 (en) * 1999-12-20 2005-06-08 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH07112936A (ja) * 1992-04-27 1995-05-02 Philippe Perovich 治療用成分、とくにアスピリンに基づく成分の製剤方法
WO2000013672A1 (en) * 1998-09-04 2000-03-16 Elan Pharma International Ltd New solid dose form of nanoparticulate naproxen

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
JP2008535846A (ja) * 2005-04-08 2008-09-04 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物
JP2013189465A (ja) * 2005-04-08 2013-09-26 Ptc Therapeutics Inc ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物
JP2007197373A (ja) * 2006-01-27 2007-08-09 Akiyama Jozai Kk 口腔内速崩錠の製造方法
JP2009544706A (ja) * 2006-07-24 2009-12-17 シマ ラブス インク． 高用量の経口的に溶解可能／分解可能な凍結乾燥剤形
JP2008189634A (ja) * 2007-02-08 2008-08-21 Akiyama Jozai Kk 口腔内速崩錠の製造方法
JP2011524386A (ja) * 2008-06-20 2011-09-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 直接圧縮性および迅速崩壊性錠剤マトリックス
US11166917B2 (en) 2008-06-20 2021-11-09 Merck Patent Gmbh Direct injection moldable and rapidly disintegrating tablet matrix
JP2016513625A (ja) * 2013-03-04 2016-05-16 ブイティーブイ・セラピューティクス・エルエルシー 安定なグルコキナーゼ活性化剤組成物
JPWO2015016256A1 (ja) * 2013-07-30 2017-03-02 ライオン株式会社 錠剤
JP2019077644A (ja) * 2017-10-25 2019-05-23 富士フイルム株式会社 医薬組成物及び医薬組成物の製造方法

Also Published As

Publication number Publication date
EP1282399A2 (en) 2003-02-12
CA2408848A1 (en) 2001-11-22
CA2408848C (en) 2009-07-21
DE60121570D1 (de) 2006-08-31
ATE333265T1 (de) 2006-08-15
EP1282399B1 (en) 2006-07-19
US6316029B1 (en) 2001-11-13
JP2011037876A (ja) 2011-02-24
WO2001087264A2 (en) 2001-11-22
WO2001087264A3 (en) 2002-06-20
AU2001263228A1 (en) 2001-11-26
DE60121570T2 (de) 2007-07-05

Similar Documents

Publication Publication Date Title
US6316029B1 (en) Rapidly disintegrating solid oral dosage form
US20080213371A1 (en) Rapidly disintegrating solid oral dosage form
JP5641682B2 (ja) 徐放性ナノ粒子組成物
US8293277B2 (en) Controlled-release nanoparticulate compositions
US9980915B2 (en) Oral disintegrating tablet
JP6514702B2 (ja) 好酸球性食道炎のためのコルチコステロイド含有口腔内崩壊錠組成物
JP2005526095A (ja) 脆砕性の低い急速溶解投与剤型
JP2004513886A (ja) 固体用量ナノ粒子組成物
JP2003516341A (ja) 治療薬
WO2022177983A1 (en) Pharmaceutical compositions of cabozantinib
US20070243248A1 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
EP1469848B1 (en) Sedative non-benzodiazepine formulations
EP1941878A1 (en) Sedative non-benzodiazepine formulations
JP2002104966A (ja) ネフィラセタム含有経口固形製剤
MXPA00001417A (en) Matrix controlled release device

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20081030

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20081201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090427

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090406

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101208

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110506

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120223